Patents Assigned to Bayer
-
Publication number: 20240376218Abstract: The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti-human, anti-cynomolgus, and/or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and/or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human, cynomolgus and/or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non-internalizing) antibodies, and antibodies efficiently inducing ADCC and/or ADCP in Treg cells.Type: ApplicationFiled: May 16, 2024Publication date: November 14, 2024Applicant: Bayer AktiengesellschaftInventors: Sandra Berndt, Christian Bertling, Pascale Buchmann, Philipp Ellinger, Katharina Filarsky, Matyas Gorjanacz, Sabine Maria Hoff, Nikolaus Pawlowski, Helge Roider, Beatrix Stelte-Ludwig, Mark Trautwein, Ernst Weber, Uwe Gritzan, Oliver von Ahsen, Christian Votsmeier, Wiebke Maria Nadler, Patrick Jones, Pedro Paz, Su-Yi Tseng, Phaik Lyn Oh
-
Publication number: 20240376103Abstract: The present invention relates to a novel and improved process for preparing (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide of the formula (I) and also to the preparation of the enantiomer (Ia) by racemate resolution using chiral substituted tartaric acid esters of the general formulae (IIIa) and (IIIb) where Ar represents a substituted or unsubstituted aromatic or heteroaromatic radical.Type: ApplicationFiled: June 13, 2024Publication date: November 14, 2024Applicants: Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventors: Johannes PLATZEK, Kai LOVIS, Winfried JOENTGEN
-
Patent number: 12138256Abstract: The present invention relates to the use of (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4?-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid of formula (I), prefer-ably in form of one of its salts or solvates or hydrates, preferably (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4?-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid in form of monohydrate (I) of formula (I-M-I) or (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4?-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)-ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid inform of mono hydrate (II) of formula (I-M-II), in the inhalative treatment of cardiopulmonary and pulmonary disorders, such as pulmonary arterial hypertension (P AH), chronic tromboembolic pulmonary hypertension (CTEPH) and pulmonary hypertension (PH) associated with chronic lung disease (PH group 3) such as pulmonary hypertension in chronic obstructive pulmonType: GrantFiled: November 10, 2023Date of Patent: November 12, 2024Assignees: Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventors: Eva Maria Becker-Pelster, Hanna Tinel, Michael Hahn, Dieter Lang, Gerrit Weimann, Johannes Nagelschmitz, Lisa Dietz, Soundos Saleh, David Jung, Ildiko Terebesi, Tobias Mundry, Annett Richter, Britta Olenik, Birgit Keil, Bernd Rösler, Peter Fey, Heiko Schirmer, Guido Becker, Clemens Bothe, Helene Faber, Julian Egger, Mark Parry, David Ward, Cecile Vitre
-
Publication number: 20240366620Abstract: The present invention features improved compounds, especially methods of identifying patients having cancer using biomarkers (e.g., PDE3A, SLFN12 and/or CREB3L1) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., Compounds 1-6 disclosed herein).Type: ApplicationFiled: July 6, 2024Publication date: November 7, 2024Applicants: BAYER PHARMA AKTIENGESELLSCHAFT, THE BROAD INSTITUTE, INC., DANA-FARBER CANCER INSTITUTE, INC.Inventors: TIMOTHY A. LEWIS, ALEX BURGIN, MONICA SCHENONE, XIAOYUN WU, HEIDI GREULICH, MATTHEW MEYERSON, LUC DE WAAL, ANTJE MARGRET WENGNER, KNUT EIS, PHILIP LIENAU, ULRIKE SACK, MARTIN LANGE
-
Publication number: 20240360098Abstract: The present disclosure relates to substituted thiophene carboxamides and analogues thereof that may be used for protecting plants from bacterial diseases, in particular from bacterial diseases caused by bacteria belonging to the genus Xanthomonas.Type: ApplicationFiled: February 29, 2024Publication date: October 31, 2024Applicant: Bayer AktiengesellschaftInventors: David Bernier, Stéphane Brunet, Jérémy Dufour, Thomas Knobloch, Lionel Nicolas, Tomoki Tsuchiya
-
Patent number: 12127558Abstract: The invention relates to solid formulations (especially water-dispersible granules) of tetramic acid derivatives and mixtures of these tetramic acid derivatives, to a process for production thereof and to the use thereof for application of the active ingredients present.Type: GrantFiled: April 12, 2019Date of Patent: October 29, 2024Assignees: Bayer Aktiengesellschaft, Bayer CropScience AktiengesellschaftInventors: Holger Egger, Reiner Fischer, Klaus Purbs, Ramona Schiffer
-
Patent number: 12122998Abstract: The present application provides materials and methods for treating a patient with one or more of Usher Syndrome Type 2A and ARRP, both ex vivo and in vivo; materials and methods for editing an USH2A gene containing a guanine deletion at nucleotide position c.2299. In addition, the present application provides one or more gRNAs or sgRNAs for editing an USH2A gene containing a guanine deletion at nucleotide position c.2299; a therapeutic comprising at least one or more gRNAs or sgRNAs for editing an USH2A gene containing a guanine deletion at nucleotide position c.2299; and a therapeutic for treating a patient with one or more of Usher Syndrome Type 2A and ARRP. The present application also provides a kit for treating a patient with one or more of Usher Syndrome Type 2A and ARRP.Type: GrantFiled: August 2, 2021Date of Patent: October 22, 2024Assignees: CRISPR THERAPEUTICS AG, BAYER HEALTHCARE LLCInventors: Mariacarmela Allocca, Akiko Noma, Abraham Scaria
-
Patent number: 12123028Abstract: This disclosure relates to methods for use in inactivating viruses. The virus inactivation methods are for use in continuous process manufacturing of a biologic such as an antibody, and include separating an eluate using a column, subjecting said eluate to an orthogonal treatment of low pH and detergent simultaneously wherein, the time for viral inactivation is reduced. In addition, the detergent can be added to buffer system in purification process to achieve the same effect. The biologic in each treatment case is retained.Type: GrantFiled: November 14, 2019Date of Patent: October 22, 2024Assignee: Bayer HealthCare LLCInventors: Shengjiang Liu, June Xiaojun Zou, Janice Hsiu Mei Lee
-
Publication number: 20240346718Abstract: Disclosed herein are systems and methods for generating artificial contrast-enhanced computed tomography (CT) images. An exemplary computer-implemented method involves receiving representations of an examination region of an examination object after administration of a contrast agent. The representations result from CT examination of the examination region at different X-ray energies. The method involves generating a representation of the contrast agent signals on the basis of the received representations (e.g., a signal intensity distribution brought about by the contrast agent in the examination region). The method involves generating a synthetic representation of the examination region comprising an ?-fold addition of the representation of the contrast agent signals to one of the received representations or to a virtual non-contrast agent representation of the examination region. ? is a negative or positive real number.Type: ApplicationFiled: April 12, 2024Publication date: October 17, 2024Applicant: Bayer AktiengesellschaftInventors: Gregor JOST, Felix Karl KREIS, Johannes HÕHNE, Gunnar SCHÛTZ, Hubertus PIETSCH
-
Publication number: 20240347206Abstract: The present disclosure relates to the early detection of the presence or occurrence of a condition in an object of investigation and/or the occurrence of an event in an object of investigation by means of machine learning methods. The subject matter of this disclosure consists of a computer-implemented method, a computer system, and a computer program for the early detection of such conditions and/or events.Type: ApplicationFiled: March 12, 2024Publication date: October 17, 2024Applicant: Bayer AktiengesellschaftInventors: Steffen VOGLER, Johannes Hohne, Matthias Lenga
-
Patent number: 12116357Abstract: The present invention relates to novel heteroaryl-triazole and heteroaryl-tetrazole compounds of the general formula (I), in which the structural elements Y, Q1, Q2, R1, R2, R3a, R3b, R4 and R5 have the meaning given in the description, to formulations and compositions comprising such compounds and for their use in the control of animal pests including arthropods and insects in plant protection and to their use for control of ectoparasites on animals.Type: GrantFiled: April 15, 2019Date of Patent: October 15, 2024Assignee: Bayer AktiengesellschaftInventors: Alexander Arlt, Werner Hallenbach, Hans-Georg Schwarz, Martin Fuesslein, Heinz-Juergen Wroblowsky, Marc Linka, Ulrich Goergens, Kerstin Ilg, Ulrich Ebbinghaus-Kintscher, Yolanda Cancho Grande, Arunas Jonas Damijonaitis, Sascha Eilmus, Andreas Turberg, Iring Heisler
-
Patent number: 12118425Abstract: A reader system for reading information on at least one identification tag associated with a syringe connected to a fluid injector has a detector and a background screen spaced apart from the detector such that at least one of the at least one identification tags is positioned in an optical path between the detector and the background screen when the syringe is connected to the fluid injector. The reader system further has an illumination system configured for illuminating at least a portion of the background screen. The detector is configured for detecting and decoding the at least one identification tag. Methods for reading information on at least one identification tag associated with a syringe are also described.Type: GrantFiled: April 11, 2023Date of Patent: October 15, 2024Assignee: BAYER HEALTHCARE LLCInventors: Christopher Capone, Jaroslaw Wlodarczyk
-
Patent number: 12119099Abstract: A system for conducting a fluid injection procedure comprises: a loading device for filling containers with fluid; an information read/write device operatively associated with the loading device and configured to: read information related to the containers stored on information storage devices associated with the containers and write information related to an injection procedure and/or a patient to the information storage devices; and a fluid injector system configured to receive the containers after filling by the loading device and inject the contents of the containers of fluid into the patient. The loading device is configured to fill the containers with fluid based on the information related to the containers read from the information storage devices. The information read/write device is configured to write information to the information storage device. The fluid injector system is configured to read the information and use this information to program the fluid injector system.Type: GrantFiled: September 10, 2019Date of Patent: October 15, 2024Assignee: BAYER HEALTHCARE LLCInventors: Kevin Cowan, Edward Liscio
-
Patent number: 12108757Abstract: The present invention relates to agrochemical compositions based on emulsion polymers; their use for foliar application and their application in aqueous crop protection flowable formulations for controlling agricultural pests, weeds or diseases and reducing the wash-off of active ingredients by rainfall.Type: GrantFiled: May 18, 2017Date of Patent: October 8, 2024Assignee: Bayer CropScience AktiengesellschaftInventors: Malcolm Faers, Howard Roger Dungworth, James Richard Wickson, Kathryn Marie Knight, James Alexander Flavell
-
Publication number: 20240331412Abstract: The present invention relates to the technical field of automatically determining the content of images. In particular, the present invention relates to a process for assigning images to predefined categories depending on their content. Subject matter of the present invention is a computer-implemented method of automatically determining to which part of an object the content depicted in one or more images belongs to, a computer system configured to execute the computer-implemented method, and a non-transitory computer-readable storage medium comprising processor-executable instructions with which to perform the computer-implemented method.Type: ApplicationFiled: July 18, 2022Publication date: October 3, 2024Applicant: Bayer AktiengesellschaftInventors: Gerard SANROMA GÜELL, Markus BLANK, Mark Alexander KLEMENS
-
Patent number: 12102793Abstract: A plunger for use with a syringe has a plunger body with a proximal end, a distal end, and a circumferential sidewall extending between the proximal end and the distal end along a plunger longitudinal axis. The plunger further has at least one resiliently deflectable retaining member having a first segment attached to the plunger body and a second segment protruding toward the distal end of the plunger body and deflectable relative to the first segment. The plunger further has at least one actuation member associated with the at least one resiliently deflectable retaining member. The at least one actuation member interacts with a piston to deflect the at least one resiliently deflectable retaining member upon rotation of the plunger relative to the piston. The plunger is engageable with the piston regardless of a rotational orientation of the piston relative to the plunger.Type: GrantFiled: January 6, 2023Date of Patent: October 1, 2024Assignee: BAYER HEALTHCARE LLCInventors: Michael Swantner, Richard Seman, Barry Tucker, Arthur Uber, III, Kevin Cowan, James Dedig, Christopher Capone, Jaroslaw Wlodarczyk
-
Patent number: 12102087Abstract: The present invention relates to active compound combinations, in particular within a fungicide composition, which comprises (A) a thiazolylisoxazoline of formula (I) and a further fungicidally active compound (B). Moreover, the invention relates to a method for curatively or preventively controlling the phytopathogenic fungi of plants or crops, to the use of a combination according to the invention for the treatment of seed, to a method for protecting a seed and not at least to the treated seed.Type: GrantFiled: June 30, 2021Date of Patent: October 1, 2024Assignee: BAYER CROPSCIENCE AKTIENGESELLSCHAFTInventors: Ulrike Wachendorff-Neumann, Sebastian Hoffmann, Pierre Wasnaire
-
Publication number: 20240317847Abstract: The present invention is related to agents capable of binding to and inhibiting or antagonizing the action of IL-11 and/or IL-11RA for the treatment and/or prevention of abnormal uterine bleeding, which comprises heavy menstrual bleeding, prolonged bleeding, altered bleeding pattern, dysmenorrhea, as well as of the underlying diseases leiomyoma and endometriosis and the use of the agent to inhibit menstruation. Furthermore, the invention provides novel IL-11 antibodies.Type: ApplicationFiled: February 24, 2022Publication date: September 26, 2024Applicant: BAYER AKTIENGESELLSCHAFTInventors: Maik Stefan Wilhelm OBENDORF, Frank SACHER, Jörg MÜLLER, Ralf LESCHE, Christian VOTSMEIER, Stephan MÄRSCH, Jan TEBBE, Philipp ELLINGER, Patrick Michael SMITH, Jenny FITTING, Katharina FILARSKY, Mathias GEHRMANN, Marcus KARLSTETTER, Ernst WEBER, Mark TRAUTWEIN
-
Patent number: 12098140Abstract: The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).Type: GrantFiled: April 13, 2023Date of Patent: September 24, 2024Assignee: Bayer AktiengesellschaftInventors: Alexandros Vakalopoulos, Marie-Pierre Collin-Kröpelin, Nuria Ortega Hernandez, Andre Dieskau, Melissa Boultadakis-Arapinis, Lisa Candish, Timo Stellfeld, Ilka Mathar, Lucas Hudson Hofmeister, Peter Sandner, Frank Wunder, Lisa Dietz, Robert Alan Webster, Carsten Schmeck, Thomas Mondritzki
-
Patent number: 12099369Abstract: An aerial vehicle includes a liquid chemical tank, at least one spray unit, a plurality of sensors, a processing unit, and an output unit. The processing unit is configured to generate a spray record for an environment within which the aerial vehicle is operating, the spray record comprising: information over a time period of at least one spray condition relating to one or more of the at least one spray unit for the aerial vehicle operating within the environment over the time period, the determined air movement direction relative to the projection of the fore-aft axis onto the ground over the time period, and the determined air movement speed relative to the ground over the time period. The output unit is configured to output the spray record.Type: GrantFiled: January 15, 2020Date of Patent: September 24, 2024Assignee: Bayer AktiengesellschaftInventor: Andrew Charles Chapple